Alterity Therapeutics (ATHE) Enterprise Value (2009 - 2025)

Alterity Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$32.3 million for Q4 2025.

• On a quarterly basis, Enterprise Value fell 988.88% year-over-year to -$32.3 million in Q4 2025; TTM through Dec 2025 was -$32.3 million, a 988.88% decrease from a year earlier, with the FY2025 full-year figure at -$21.3 million, down 154.46% from the prior year.
• Enterprise Value slipped to -$32.3 million in Q4 2025 per ATHE's latest filing, from -$21.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$153190.1 in Q2 2024 and bottomed at -$32.3 million in Q4 2025.
• The 5-year median for Enterprise Value is -$21.5 million (2021), against an average of -$16.4 million.
• Across the five-year window, Enterprise Value surged 99.26% in 2023 and plunged 13779.93% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$27.0 million in 2021, then increased by 15.16% to -$22.9 million in 2022, then surged by 55.1% to -$10.3 million in 2023, then surged by 71.11% to -$3.0 million in 2024, then slumped by 988.88% to -$32.3 million in 2025.
• Per Business Quant, the three latest ATHE Enterprise Value figures stand at -$32.3 million (Q4 2025), -$21.3 million (Q2 2025), and -$3.0 million (Q4 2024).